MPN
Myeloproliferative neoplasms (MPNs) are diseases of the blood cells and bone marrow. MPNs involve dysregulation at the multipotent hematopoietic stem cell (CD34). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.
Hematocrit control was “suboptimal” in more than half of patients with high-risk polycythemia vera.
Ruben Mesa, MD, discusses his career in MPN treatment and research and notable abstracts at the 2022 ASH Annual Meeting.
Srdan Verstovsek, MD, discusses using machine learning to predict resistance to hydroxyurea therapy in polycythemia vera.
Patients with MPN have a high risk of death from cardiovascular causes.
Patients with MPN who are employed face a “high economic burden,” especially if they experience thrombotic events.
Statin use may reduce the risk of developing a myeloproliferative neoplasm (MPN), according to a recent study.
Chadi Nabhan, MD, MBA, FACP, interviews Srdan Verstovsek, MD, on highlights in MPN research at the 2022 ASH Annual Meeting.
Srdan Verstovsek, MD, discusses the phase III VERIFY trial of rusfertide in patients with polycythemia vera.
Whole blood mutation allele frequency had only weak prognostic value in certain patients with polycythemia vera.
Several factors were independently associated with arterial thrombotic events in patients with myeloproliferative neoplasms.
Symptom-related quality of life is linked with the type of cytoreductive treatment used for MPNs.
The combination of interferon and ruxolitinib may be a treatment option for newly diagnosed polycythemia vera.
Long-term follow-up results of a phase II study of ruxolitinib in patients with MPNs were presented at the 2022 ASH Meeting.
New data support the use of ropeginterferon alfa-2b therapy in patients with low-risk or high-risk PV,
An analysis of patients with MF found that the combination of navitoclax and ruxolitinib reduced MF-associated splenomegaly.
IFNα2 treatment may help reduce the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms ...
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
The National Comprehensive Cancer Network publishes new MPN guidelines.
Researchers published new classifications for MPNs and acute leukemias.
Transfusion independence was associated with improved survival in studies of momelotinib in patients with myelofibrosis.
As TKIs have become available to patients, survival for those with CML has significantly improved but disparities.
VERIFY, a phase III trial of the hepcidin mimetic rusfertide (PTG-300), is now enrolling patients with PV.
IFN alpha-2 influences the regulation of several ECM genes involved in tissue remodeling.
A large real-world study assessed patients who were diagnosed with myeloproliferative neoplasms before age 25.
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Study finds BM CH was present in nearly two-thirds of BPDCN patients and particularly prevalent in elderly patients.
Pankit J. Vachhani, MD, and Srdan Verstovsek, MD, debate the usefulness of variant allele frequency (VAF).
Long-term results from the RESPONSE-2 trial confirm efficacy of ruxolitinib for PV.
The NCCN now includes the oral JAK inhibitor pacritinib as a first-line treatment for certain myelofibrosis patients.
In patients with high-risk essential thrombocythemia and polycythemia vera, both hydroxyurea and pegylated interferon-α.
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
REVEAL is the largest prospective and contemporary cohort of patients with PV in the United States.
Researchers shared a new single-cell multi-omic analysis of the genetic, cellular, and molecular landscape of TP53-driven.
Clonal hematopoiesis of indeterminate potential was associated with a reduced risk of Alzheimer's disease dementia.
A study evaluated factors associated with intense end-of-life care among patients younger than 40 with blood cancer.
A research team in Norway found that previous hematological malignancies were associated with a subsequent diagnosis.
Advertisement
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
